The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities.

2^nd World Congress Virology and Infectious disease
Date: September 3-4, 2019
Venue: London, UK
URL:  https://bit.ly/2q62wrS 

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities.

Zika virus (ZIKV) the outbreak has emerged as a worldwide health threat, significantly in tropical areas, over the past few years.

No antiviral medical care or vaccine is out there at present. For these reasons, repurposing clinically approved medicine against ZIKV infection might give fast and cost‐effective world health edges.

Here, we have a tendency to explored this strategy and screened eight FDA‐approved medicine for antiviral activity against ZIKV employing a cell‐based assay.

Our results show that the antiprotozoal drug amodiaquine has anti‐ZIKV activity with EC50 at low micromolar concentrations in cell culture.

We have a tendency to additional characterized amodiaquine antiviral activity against ZIKV and located that it targets early events of the infectious agent replication cycle.

Altogether, our results recommend that amodiaquine is also efficacious for the treatment of ZIKV infection.

To know more about virology and infectious disease, attend an event on Antiviral Vaccines at Virology Summit

Contact details
Clara Charlotte
Program Manager | Virology 2019
Email:virology@microbioconferences.com

Phone: +44 20 3769 1755